Crossing the cancer cell membrane to improve clinical outcomes.
Rowinsky
Eric K
EK
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA. erowinsky@saci.org
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000187:drug effects*; D016503:Drug Delivery Systems / Q000639:trends*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000187:drug effects; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects*; D018631:ras Proteins / Q000187:drug effects
D000911:Antibodies, Monoclonal; D004921:Erythropoietin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011994:Recombinant Proteins; D018631:ras Proteins